MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
DBV Technologies S.A. Operating Income 2011-2026 | DBVT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income DBV Technologies S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -117 M | -76.4 M | -96.6 M | -98.6 M | -159 M | -171 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -76.4 M | -171 M | -120 M |
Quarterly Operating Income DBV Technologies S.A.
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -41.1 M | -26.6 M | -30.3 M | -33.8 M | -28.6 M | -18.3 M | -25.1 M | -21.2 M | - | -18 M | -23.8 M | -16.8 M | - | -24.4 M | -31.1 M | -29.6 M | - | -29.8 M | -47.7 M | -41.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -16.8 M | -47.7 M | -28.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-163 M | $ 18.24 | -1.41 % | $ 2.68 B | USA |
 |
Amgen
AMGN
|
7.26 B | $ 344.45 | 0.75 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
98.3 M | $ 73.14 | 5.5 % | $ 9.78 B | USA |
 |
Biogen
BIIB
|
7.04 B | $ 178.43 | -0.81 % | $ 26 B | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.7 | 3.85 % | $ 17 M | USA |
 |
Adagene
ADAG
|
-36 M | $ 2.87 | 4.36 % | $ 162 M |  China |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.77 | 0.83 % | $ 1.59 B | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-46.3 M | $ 1.39 | -1.42 % | $ 261 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 222.86 | -1.43 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 4.12 | 2.74 % | $ 8.96 B |  Israel |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 109.1 | -4.09 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.39 | 1.09 % | $ 355 M | Britain |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Cardiff Oncology
CRDF
|
-48.7 M | $ 1.75 | -0.29 % | $ 83.4 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Compugen Ltd.
CGEN
|
-14.9 M | $ 1.85 | 0.54 % | $ 166 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
249 M | $ 14.11 | 3.14 % | $ 4.36 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-2.54 M | $ 6.64 | 0.91 % | $ 1.37 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Beam Therapeutics
BEAM
|
-416 M | $ 27.95 | 1.19 % | $ 2.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |